- AngelsRound
- Posts
- RonanRX 💊
RonanRX 💊
Personalized medicine for GLP-1s and peptides.
Spotlight
What if your prescription could change as your body responds to it?
Quick Pitch: RonanRX is building personalized medicine for peptides and GLP-1s, using patient data and treatment response to help physicians adjust medication, then compounding and delivering it through its own pharmacy.
The Problem
Standardized Dosing: GLP-1s largely follow predefined doses even though patients can respond differently to the same medication.
Fragmented Care: Patient data, doctors, pharmacies, manufacturing, and delivery often sit across separate systems.
Limited Feedback: Labs, wearable data, and treatment response are rarely connected continuously to prescribing decisions.
Why It Matters
GLP-1s have created a large market for ongoing pharmaceutical treatment, but treatment remains largely standardized.
As adoption grows, the next opportunity may shift from simply providing access to personalizing treatment around how each patient responds.
That creates a new infrastructure challenge: connecting patient data, prescribing, pharmacy, and outcomes.
Snapshot
Industry: Personalized Medicine
Headquarters: San Francisco, CA
Founded: 2026 (YC S26)
Funding: Raising $10M (Seed), Previously raised $3.3M (Pre-Seed)
Backed By: Y Combinator
Traction: Hundreds of thousands in early revenue, growing double digits week over week; licensed across 30+ states
Business Model: Recurring direct-to-patient pharmaceutical care
Founder’s Edge
Lloyd Armbrust, Co-Founder, CEO: 2x YC founder with three exits who previously built a U.S. medical manufacturing business.
Emily Colman, Co-Founder, COO: Spent a decade in healthcare, including experience at Eli Lilly and AbbVie across peptide therapeutics and GLP-1 strategy.
Playing Field
Telehealth Platforms: Hims & Hers, Ro, Found, and WeightWatchers Clinic provide patient access but rely on outside pharmacies.
Compounding Pharmacies: Can manufacture personalized prescriptions but typically do not own the clinical workflow or patient data.
RonanRX's Edge: Combines patient data, physician oversight, compounding, delivery, and treatment outcomes in one system.
Analysis
Bulls Case 📈
Early revenue and word of mouth growth suggest initial demand.
Repeat YC founder with multiple exits reduces early execution risk.
Physician onboarding creates distribution beyond direct-to-consumer acquisition.
More patients could create a richer dataset linking treatment decisions to outcomes.
Bears Case 📉
Personalized compounding adds regulatory and operational complexity.
Larger telehealth platforms could integrate more of the care stack.
Owning prescribing, manufacturing, and delivery makes scaling more complex.
Early traction is too recent to establish retention or durable growth.
Verdict
RonanRX's most interesting asset may eventually be the data created by owning the treatment loop.
Connecting patient characteristics, prescriptions, doses, and outcomes could create a data advantage that improves with scale and extends beyond GLP-1s.
The question is whether that advantage compounds faster than the complexity of owning the stack.
The Startup Pulse
Another happening week in startup funding. Three signals from this week:
AI infrastructure is expanding beyond GPUs
Reliability and security are becoming major agent categories
AI is reshaping existing markets from software to energy
Crusoe: Raised $3.9B at $30.9B. With $140B+ contracted, AI data centers are becoming utility-scale infrastructure.
Temporal: Secured $550M at $12.55B. As AI agents run longer workflows, reliability is becoming critical infrastructure.
Barq: Landed $329.5M at $1.85B. With 15M+ users, Saudi Arabia is producing tech companies at a serious scale.
Strategic breakdowns of how the biggest AI companies actually work — their business models, their moats, their vulnerabilities. This week: we dissect how AI disrupted Chegg
Written by Ashher
